Health Care • Biotechnology: Pharmaceutical Preparations
$57.49 ▲ +1.49
(+2.66%)
MKT CAP: $11.13B • VOL: 2.62M
52W L $49 52W H $71
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$48
MEDIAN
$64
MEAN
$66
HIGH
$78
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE BMRN TAPE
BMRN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $69.56 | $66.11 | 2025-02-14 | $52.32 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $72.44 | $67.84 | 2025-02-06 | $54.04 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $65.54 | $63.24 | 2025-01-29 | $55.19 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $58.64 | — | 2025-01-17 | $56.34 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $50.59 | $54.62 | 2025-01-09 | $51.17 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $68.41 | $59.79 | 2024-12-18 | $50.02 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $55.77 | $58.06 | 2024-12-04 | $53.47 | -4.3% | 48% | C |